Who is sponsoring NCT05014945?

NCT05014945 is sponsored by Gangnam Severance Hospital.

What drugs are being tested in NCT05014945?

Interventions in NCT05014945: (atelocollagen group).

What condition does NCT05014945 study?

NCT05014945 studies Degenerative Lumbar Spine Disease.

Is NCT05014945 still recruiting?

NCT05014945 is currently completed. Last updated 9 August 2022.

Last reviewed 2022-08-09 · How we verify

NCT05014945

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Combination Therapy With Atelocollagen in Epidural Nerve Block

Completed NA Last updated 9 August 2022

What this trial tests

NA trial testing (atelocollagen group) in Degenerative Lumbar Spine Disease in 20 participants. Completed in 27 May 2022.

Timeline

16 August 2021

Primary endpoint
27 May 2022

27 May 2022

Quick facts

Lead sponsor	Gangnam Severance Hospital
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	20
Start date	16 August 2021
Primary completion	27 May 2022
Estimated completion	27 May 2022
Sites	1 location across South Korea

Drugs / interventions tested

(atelocollagen group)

Conditions studied

Degenerative Lumbar Spine Disease — all drugs for Degenerative Lumbar Spine Disease →

Sponsor

Gangnam Severance Hospital

Who can join

21 and older, any sex, with Degenerative Lumbar Spine Disease. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

"In this study, the investigators plan to evaluate muscle mass and pain relief 4 weeks after performing epidural nerve block and Type I porcine atelocollagen injection into multifidus muscle in patients with chronic low back pain due to degenerative spinal disease for more than 6 months.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other Gangnam Severance Hospital trials

Trials by the same sponsor.

NCT07505628 — AI-based Rehabilitation for Hip and Knee Surgery Patients · NA · not yet recruiting
NCT07311122 — Endocrine Therapy Base on 21-gene RS · not yet recruiting
NCT07011823 — Immune-checkpoint Blockade After Partial Breast Irradiation by Pembrolizumab in Early TNBC · Phase 2 · not yet recruiting
NCT07211451 — Axillary Nodal Burden in HER2+ and TNBC · completed
NCT06839716 — Comparison of Ropivacaine-Poloxamer 407 Hydrogel and TAP Block for Postoperative Pain Management in Laparoscopic/Robotic · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05014945 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Gangnam Severance Hospital
Last refreshed: 9 August 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05014945.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing